單株抗體相關共同研究及授權契約:2019年～2025年

Monoclonal Antibody Collaboration and Licensing Deals 2019-2025

出版日期: 2025年05月01日 | 出版商:

Current Partnering | 英文 350+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告全面解讀了由世界領先生物製藥公司簽署的單株抗體協議，並提供了前所未有的存取權限。

本報告詳細解讀並分析了公司簽訂單株抗體協議的方式和原因。這些協議通常涉及多個方面，通常從合作研發開始，直到成果商業化。

合作協議涵蓋各種類型的合作協議，包括合作研發和授權協議。

本報告提供了自2019年以來已宣布的670份單株抗體相關協議的完整列表，並儘可能包含財務條款。此外，報告還提供了每份協議的線上記錄鏈接，方便您參考實際公開的協議。此外，記錄中還包含公司和/或合作夥伴向美國證券交易委員會 (SEC) 提交的合約文件（如有）。

主要優勢：

了解 2019 年及以後的交易趨勢
查看單株抗體合作與授權協議
基準分析：確定交易的市場價值
詳細的財務條款：首付款、里程碑付款、特許權使用費
按公司名稱 (A-Z)、交易類型和治療領域排序的交易目錄
依價值排序的熱門交易案例
最活躍的交易撮合者
確定每筆交易的資產和條款
存取合約文件：深入了解合約結構
盡職調查：評估擬議合約條款是否適合您的合作夥伴
節省數百小時的研究時間

合約分析可讓您對以下內容進行盡職調查：

具體授予或選擇哪些權利？
合約實際上賦予了合作夥伴什麼？
授予了哪些獨家權利？
合約的付款結構是怎樣的？
如何審計銷售和付款？
合約期間（生效期間）是多久？
合約的主要條款是如何界定的？
如何處理知識產權 (IPR)，由誰持有？
誰負責商業化？
誰負責開發、供應和生產？
如何管理保密性和成果揭露？
如何解決爭議？
合約在什麼情況下可以終止？
如果公司所有權發生變化，合約會怎樣？
如何約定再授權和分包條款？
公司通常會包含哪些 "範本條款" ？
根據合約當事人和合約類型，有哪些 "範本條款" ？
公司要求哪個司法管轄區作為合約法的適用法律？

This report contains a comprehensive listing of 670 monoclonal antibody deals announced since 2019 including financial terms where available including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2019.

Chapter 3 provides an overview of the leading monoclonal antibody deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of monoclonal antibody deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2019. The chapter is organized by specific monoclonal antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in monoclonal antibody deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2019
Browse monoclonal antibody collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Monoclonal Antibody Collaboration and Licensing Deals includes:

Trends in monoclonal antibody dealmaking in the biopharma industry
Directory of monoclonal antibody deal records covering pharmaceutical and biotechnology
The leading monoclonal antibody deals by value
Most active monoclonal antibody licensing dealmakers
Monoclonal Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in monoclonal antibody dealmaking

2.1. Introduction
2.2. Monoclonal antibody deals over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody deals by deal type
2.5. Monoclonal antibody deals by therapy area
2.6. Monoclonal antibody deals by industry sector
2.7. Deal terms for monoclonal antibody deals
- 2.7.1 Monoclonal antibody deals headline values
- 2.7.2 Monoclonal antibody deal upfront payments
- 2.7.3 Monoclonal antibody deal milestone payments
- 2.7.4 Monoclonal antibody royalty rates